The association between tumor mutational burden and prognosis is dependent on treatment context

In multiple cancer types, high tumor mutational burden (TMB) is associated with longer survival after treatment with immune checkpoint inhibitors (ICI). The association of TMB with survival outside of the immunotherapy context is poorly understood. We analyzed 10,233 patients (80% non-ICI-treated, 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Valero, Cristina, Lee, Mark, Hoen, Douglas, Wang, Jingming, Nadeem, Zaineb, Patel, Neal, Postow, Michael A., Shoushtari, Alexander N., Plitas, George, Balachandran, Vinod P., Smith, J. Joshua, Crago, Aimee M., Roche, Kara C. Long, Kelly, Daniel W., Samstein, Robert M., Rana, Satshil, Ganly, Ian, Wong, Richard J., Hakimi, A. Ari, Berger, Michael F., Zehir, Ahmet, Solit, David B., Ladanyi, Marc, Riaz, Nadeem, Chan, Timothy A., Seshan, Venkatraman E., Morris, Luc G.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796993/
https://www.ncbi.nlm.nih.gov/pubmed/33398197
http://dx.doi.org/10.1038/s41588-020-00752-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796993/
https://www.ncbi.nlm.nih.gov/pubmed/33398197
http://dx.doi.org/10.1038/s41588-020-00752-4

Ejemplares similares